EXV4:XETRA:XETRA-iShares STOXX Europe 600 Health Care UCITS ETF (DE) (EUR)

ETF | Others |

Last Closing

USD 113.52

Change

+0.42 (+0.37)%

Market Cap

USD 0.70B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.80 (-1.54%)

USD 426.26B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.33 (-1.97%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

-0.13 (-0.46%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.13 (-0.44%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

-0.23 (-0.93%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

-0.23 (-0.49%)

USD 104.42B
8R80:XETRA Amundi Index Solutions - Amund..

-0.86 (-0.60%)

USD 104.42B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

-0.28 (-0.54%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

+0.39 (+0.37%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+2.70 (+0.45%)

USD 80.38B

ETFs Containing EXV4:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.52% 48% F 51% F
Dividend Return 1.49% 26% F 24% F
Total Return 9.01% 51% F 54% F
Trailing 12 Months  
Capital Gain 12.35% 49% F 52% F
Dividend Return 1.56% 23% F 22% F
Total Return 13.91% 53% F 55% F
Trailing 5 Years  
Capital Gain 30.83% 59% D- 62% D
Dividend Return 8.67% 51% F 38% F
Total Return 39.50% 63% D 63% D
Average Annual (5 Year Horizon)  
Capital Gain 6.68% 54% F 53% F
Dividend Return 7.63% 57% F 56% F
Total Return 0.94% 63% D 44% F
Risk Return Profile  
Volatility (Standard Deviation) 8.48% 67% D+ 74% C
Risk Adjusted Return 89.89% 86% B+ 88% B+
Market Capitalization 0.70B 71% C- 63% D

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike